Latest news with #Voltron
Geek Culture
16 hours ago
- Business
- Geek Culture
Warner Bros. Reportedly Eyed Michael Bay To Direct Henry Cavill Superman Sequel
The Man of Steel, starring Henry Cavill, could have gotten another solo outing on the silver screen, but the onboarding of James Gunn and Peter Safran as DC Studios co-heads put an end to the idea. Per The Wrap, Warner Bros. Pictures chiefs Mike De Luca and Pam Abdy were considering a 'standalone Henry Cavill-led Superman film going in 2022,' with Transformers helmer Michael Bay, who has never done a straight-up superhero movie before, in the director's chair. While it's unclear how far the deal went, the project was reportedly meant to be straightforward and without the entanglements that follow tie-ins, crossovers, or multiverse productions. The discussion took place between the departure of the previous head, Walter Hamada, and the induction of Gunn and Safran. In the same year, Cavill would step down as the titular superhero and set his sights on other franchise deals, including a live-action Voltron film adaptation, a Warhammer 40K series for Amazon, and a reboot of the 1986 classic Highlander . As for Bay, the filmmaker is set to debut his first-ever documentary, We Are Storror , at the 2025 SXSW (pronounced 'South by Southwest') festival. Next on his agenda list are Netflix's action title Fast and Loose , which will reunite him with Bad Boys star Will Smith, and a film adaptation of the classic arcade title OutRun starring Sydney Sweeney. But first, all eyes are on Gunn's upcoming Superman movie. This time, David Corenswet ( Twisters , Pearl ) is donning the cape, with Rachel Brosnahan ( The Marvelous Mrs. Maisel ) and Nicholas Hoult (the X-Men films) playing Lois Lane and Lex Luthor, respectively. The superhero flick is one of the six live-action big-screen projects planned for Chapter One of the rebooted cinematic universe, followed by Supergirl: Woman of Tomorrow in June 2026, Clayface in September 2026, The Authority (TBA), The Brave and the Bold , and Swamp Thing . It hits theatres on 10 July. Si Jia is a casual geek at heart – or as casual as someone with Sephiroth's theme on her Spotify playlist can get. A fan of movies, games, and Japanese culture, Si Jia's greatest weakness is the Steam Summer Sale. Or any Steam sale, really. Man of Steel michael bay Superman Transformers warner bros
Yahoo
5 days ago
- Business
- Yahoo
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Second Oncology Candidate (VTX-0P4) in a Prostate Stem Cell Antigen (PSCA) Related Tumor Study in Combination with a Checkpoint Inhibitor (CPI) / anti-mPD-1
Study conducted at The Massachusetts General Hospital's Vaccine and Immunotherapy Center demonstrated highly significant improvements in Overall Survival and other key endpoints VTX-0P4, in combination with a CPI, had a statistically significant improvement in survival versus a CPI alone Key targets include Urothelial, Prostate, and Renal Cancers VTX-0P4 produced a safety profile similar to that seen in the control group and without evidence of reactogenicity NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, announced today that data from Study VTX-IO-004 demonstrated clear proof-of concept for the self-assembling therapeutic, VTX-0P4, in the treatment of cancers over-expressing prostate stem cell antigen (PSCA). VTX-0P4 is a novel, modular, protein-based therapy candidate designed to provide a specific therapeutic T cell mediated immunogenic response to PSCA-expressing tumors. Prior VTX-0P4 immunogenicity studies demonstrated robust overall antigen-specific T cell responses for both CD4+ and CD8+ T cell populations, in a murine model. PSCA is a critical marker in several primary cancers, including bladder, prostate, and pancreatic cancers. The primary objective of study VTX-IO-004 was to evaluate the anti-tumor effect of VTX-0P4 in a well-established mouse model utilizing PSCA-expressing TRAMP-C2 (T-C2) tumors. A key secondary objective was to evaluate the anti-tumor effect of VTX-0P4 in combination with a checkpoint inhibitor (CPI). Treatment with VTX-0P4 induced robust, statistically significant antigen specific cellular immune responses and anti-tumor effects compared to controls. In addition, the combination of VTX-0P4 with a CPI demonstrated statistically highly significant additive efficacy benefit over VTX-0P4 or a CPI as monotherapy. This study provides further evidence supporting the utility of Voltron's modular immunotherapeutic platform, demonstrating its ability to enhance targeted oncologic immune responses when combined with a well-established tumor associated antigen and a CPI. These results add important potential indications to Voltron's growing pipeline which includes HPV positive cervical and head and neck cancers. Results of the study demonstrated: Improved Overall Survival: VTX-0P4 + anti-mPD-1 had a highly significant, positive survival effect in the TC-1 tumor injected mice versus anti-mPD1 alone Tumor volume reduction: VTX-0P4 + PD-1 significantly slowed/reduced growth in T-C2 tumor volume Dose response: there was a clear dose-response to the combination which matched the previously reported immunogenicity results (i.e., the T cells are getting to their target) Safety Profile: the SAV construct was well tolerated with no observed reactogenicity. Dr. Mark Poznansky, a Scientific Founder of Voltron Therapeutics Inc and Director, Vaccine and Immunotherapy Center, MGH commented: 'These data clearly demonstrate that this novel tumor targeting platform, when combined with a PD-1 inhibitor, significantly controlled tumor growth and augmented survival versus VTX-0P4 or a CPI alone. Additionally, these results are significant because it has now been shown that an effective cell mediated response against a self antigen, namely PSCA, can be generated by VTX-OP4. This supports the view that this novel self-assembling immunotherapy could be broadly applicable to a wide variety of cancers that are known to express tumor specific antigens.' Patrick J. Gallagher, Voltron's Chief Executive Officer stated, 'The results of this rigorously designed study highlight the great promise of Voltron's platform technology. The VTX-0P4 responses, as measured by survival and tumor volume, were significantly enhanced when combined with a CPI / PD-1. Physiologically this makes sense. As the anti-mPD-1 removes the tumor's ability to 'escape' the immune system, it creates a tumor microenvironment (TME) that's more accessible to classic T cell-specific antitumor effects. Our approach activates and significantly increases the percentage of PSCA-specific antitumor T cells seeking to enter the TME, thus complementing the PD-1 inhibition mechanism of action.' This important research and development milestone further demonstrates and supports the therapy platform's unique capabilities: utility in driving efficacy in combination therapy, development speed, target/pathogen flexibility and significant engagement of the immune system. This work with a full-length protein dramatically expands the breadth of potential value/solutions that the platform could offer in the oncology and infectious disease settings. 'Checkpoint inhibitors and other immunotherapies have dramatically improved outcomes for many cancer patients. Nonetheless there are still significant opportunities to improve patient outcomes through combination therapies with complimentary mechanisms,' said James Ahern, Managing Partner of Laidlaw & Company and founder of Lucius Partners. 'Our safety profile and compelling efficacy data could make us an ideal addition to current treatment algorithms. The Voltron team will continue to leverage our highly flexible platform to create new solutions for clinicians and patients and value for our shareholders.' About Voltron Therapeutics, Inc. Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel platform technology in a variety of indications, including in Oncology and Emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and development team, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (including Lassa Fever) as well as six oncology indications (HPV Related Cancers, PSCA related cancers). For more information, please visit About Lucius Partners, LLC Lucius Partners is a consultancy that provides a broad suite of services to help healthcare companies grow, achieve milestones and generate value for their shareholders. Forward Looking Statements This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as 'anticipate', 'being', 'will', 'plan', 'may', 'continue', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law. Contact: Patrick Gallagher, CEO Voltron Therapeutics, Inc. Managing Partner Lucius Partners, LLCpgallagher@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Tyrant
26-05-2025
- Entertainment
- Geek Tyrant
Live-Action VOLTRON Movie Wraps Filming and Promises a True Fan Experience — GeekTyrant
The long-awaited live-action Voltron movie has wrapped filming, and according to the team behind it, fans are in for something special. The project has been floating around Hollywood for years, like so many other nostalgic properties with strong fanbases. But now, thanks to Amazon MGM Studios and World Events Productions, Voltron is actually happening. The production kicked off last year, and after months of updates, casting reveals, and set teases, the finish line for filming has been crossed. The official Voltron Instagram page shared a behind the scenes update from Bob Koplar and the World Events team, confirming that principal photography is complete and dropping a few hints about what comes next. 'Our live-action Voltron film has officially wrapped production, and we're THRILLED with how it all went. I've been with this franchise for years and can proudly say that this WILL be the Voltron experience our fans have been dreaming of.' Well, that's sure to raise expectations. Fans have been burned before by live-action takes on beloved animated series, but maybe this movie will actually deliver. The update also addressed one of the more persistent rumors… that the movie might skip theaters and head straight to streaming. 'There's been some chatter out there about the plans for the film's launch and we'd like to assure you, when official plans are set for the film, you will be the the first to hear it right here. 'Stay with us! I promise it'll be worth the wait!' So while there's still no release date or platform confirmed, the studio clearly wants to keep options open—and the hype high. Directed by Rawson Marshall Thurber ( Red Notice , Central Intelligence ), who also co-wrote the script with Ellen Shanman, the film is aiming for blockbuster scale. The cast includes Daniel Quinn-Toye who is stepping into the lead role, joined by a lineup that includes Henry Cavill, Sterling K. Brown, Rita Ora, John Kim, Alba Baptista, Samson Kayo, and Tharanya Tharan. No story details have been revealed yet, but with filming complete, fans can expect more news to drop in the coming months as post-production rolls forward. I just hope the movie get a a big theatrical release! I want to watch this on the big screen!
Arabian Business
01-05-2025
- Business
- Arabian Business
Logistiya officially launched under presence of Deputy Minister of Transport and Logistics, paving the way for a new era in Saudi logistics
Logistiya, a fully owned subsidiary of Innovest and a next-generation enabler of logistics infrastructure, officially launched yesterday in Riyadh under the presence of His Excellency Eng. Rayan Al Bakri, Deputy Minister of Transport and Logistics Services. The event marked a major milestone in Saudi Arabia's journey toward becoming a global logistics powerhouse. Rooted in the Kingdom's Vision 2030 and driven by the national ambition to become a global logistics hub, Logistiya was established to accelerate the development of logistics parks, warehousing hubs, bonded zones, and strategic infrastructure across the country. The launch event gathered key partners, industry leaders, and government stakeholders to showcase Logistiya's mission, capabilities, and first flagship developments. During the event, Mr. Mohammed Al Khars, Chairman of Innovest Properties, took the audience through the story behind the inception of Logistiya. 'Similar to the residential development boom in 2016–2017, logistics and industrial development today is witnessing a similar growth trajectory—one that is becoming a cornerstone of economic expansion in the Kingdom,' he said. 'Logistiya is our answer to that opportunity, grounded in the same principles that built our success in the real estate sector: vision, partnerships, and execution.' 'We are on a mission to enable smarter, faster, and more sustainable logistics infrastructure across the Kingdom,' said Mario El Khoury, CEO of Logistiya. 'We believe that Saudi Arabia has the fundamentals to become the logistics capital of the region — and we are here to help make that happen.' Backed by Innovest's track record in real estate and development since 2017, Logistiya combines local insight with global best practices, forming strategic partnerships across engineering, investment, and operations to ensure world-class execution. The company's integrated model — spanning 'Develop, Activate, and Operate' — positions it uniquely to deliver scalable, efficient, and tech-enabled logistics ecosystems. The launch also featured the unveiling of Logistiya's first flagship warehousing complex in Riyadh, scheduled to go live in 2026. The project—developed in partnership with Rikaz, represented by its Chairman and CEO Mr. Khalid bin Hassan Al-Qahtani—is valued at 230 million SAR and will be located on a 77,500 sqm plot within The Node city in East Riyadh. It will feature a state-of-the-art, temperature-controlled Class A warehousing facility. As part of its ambitious growth strategy, Logistiya announced the signing of an exclusive five-year partnership with Voltron Technology, a U.S.-based leader in high-performance computing (HPC) data center solutions. The partnership marks Voltron's entry into the Saudi market and positions Logistiya as the exclusive local enabler for HPC infrastructure developments. Voltron's cutting-edge systems and AI-native designs bring advanced digital capabilities that align perfectly with Logistiya's vision of smart logistics hubs powered by intelligent systems and data-driven operations. 'Technology and infrastructure must evolve together. Our partnership with Voltron ensures we are ready for the next generation of logistics—integrated, automated, and digitally enabled,' added El Khoury. 'Saudi Arabia is one of the most exciting markets in the world today,' said Steven Greenberg, Chairman of Voltron. 'The ambition of Vision 2030, the next-generation thinking of the Kingdom's leadership, and the sheer scale of opportunity across logistics and technology are truly inspiring. Logistiya is exactly the kind of strategic, forward-thinking partner we sought—deeply rooted in the market, yet bold enough to help drive real transformation.' In a further move to future-proof the Kingdom's logistics ecosystem, Logistiya also announced the upcoming launch of a Saudi-based Logistics Accelerator Program in partnership with Quay Acceleration, a leading U.S. accelerator based in New York. Since its founding in 2016, Quay has accelerated more than 500 companies globally and helped startups raise over $1 billion in funding. Set to begin in 2025, the program will attract global startups specialising in LogiTech, FinTech, and PropTech to establish operations and pilot solutions in Saudi Arabia. The initiative aims to foster innovation, localise emerging technologies, and build a robust digital backbone for industrial and logistics development. The launch event was followed by an official dinner, where attendees gathered to celebrate the milestone and engage in deeper discussions on collaboration, innovation, and investment in the logistics sector. As Saudi Arabia accelerates its localisation, trade facilitation, and digital transformation efforts, Logistiya stands ready to deliver the infrastructure, partnerships, and innovation required to power the Kingdom's logistics future.
Yahoo
01-04-2025
- Entertainment
- Yahoo
Four fab Beatles movies are coming to theaters in April 2028
Help! At CinemaCon, Sam Mendes confirmed that his long-threatened Beatles biopic quadrilogy would be released in its entirety in April 2028. That's right, all four Beatles movies want to hold their hands, so Sony is releasing them helter-skelter in theaters in the same month. Based on the logline ('Each man has his own story, but together they are legendary'), we believe the plan is still to do a movie for each Beatle to combine into an interlocking cinematic Voltron. Sony also made its cast official, too, with Harris Dickinson as John Lennon, Paul Mescal as Paul McCartney, Barry Keoghan as Ringo Starr, and Joseph Quinn as George Harrison. All this raises more questions, such as who's playing Brian Epstein and George Martin? How many years will it cover? Will the Blue Meanies be involved? We simply do not know. All we know is that each man has his own story, but together they are legendary. The Beatles — A Four-Film Cinematic Event overwhelms theaters in April 2028. More from A.V. Club Podcast Canon: Beef And Dairy Network's commitment to the bit is practically unheard of The Gemstones set a parent trap in a masterful vacation episode Four fab Beatles movies are coming to theaters in April 2028
